Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

R 21

Next Previous
Drug Profile

R 21

Alternative Names: Malaria virus-like particle vaccine - MultiMalVax; Matrix-M; Plasmodium falciparum circumsporozoite protein/HBsAg subunit vaccine - Multimalvax; R-21; R21/Matrix-M; R21/Matrix-M adjuvanted malaria vaccine; R21/Matrix-M™ malaria vaccine; R21/MM

Latest Information Update: 25 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Oxford
  • Developer GSK; Serum Institute of India; University of Oxford
  • Class Antimalarials; Malaria vaccines; Parasitic vaccines; Subunit vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Falciparum malaria

Most Recent Events

  • 20 Mar 2024 University of Oxford in collaboration with Bill and Melinda Gates Foundation and University Hospitals Bristol and Weston NHS Foundation initiates a phase I trial in Falciparum malaria (Prevention) in the UK (IM) (NCT06320535)
  • 04 Feb 2024 Updated adverse event data from a phase III trial in Falciparum malaria released by Novavax
  • 01 Feb 2024 Updated efficacy and adverse event data from a phase III trial in Falciparum malaria (In Children, In infants, Prevention) released by Serum Institute of India
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top